Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.39 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7751825 | 0.94 | MEN1 (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2PAOX | |
| SCHEMBL12927099 | 0.85 | SIGMAR1 (0.49) | MEN1KMT2ASIGMAR1MAPK1 | |
| SCHEMBL16853212 | 0.82 | ALDH1A1 (0.55) | MEN1KMT2AALDH1A1SMN1; SMN2PAOX | |
| SCHEMBL13374393 | 0.82 | CASP2 (0.48) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL21015239 | 0.82 | MEN1 (0.46) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL13374395 | 0.82 | CASP2 (0.48) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL13374396 | 0.82 | MEN1 (0.46) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL18513030 | 0.82 | MEN1 (0.71) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL24611784 | 0.80 | ALDH1A1 (0.59) | MEN1KMT2AALDH1A1SMN1; SMN2PAOX | |
| SCHEMBL14198854 | 0.80 | ALDH1A1 (0.59) | MEN1KMT2AALDH1A1SMN1; SMN2PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | CRBN, MDM2, RBX1 | MEN1 1285/4885KMT2A 1310/4885ALDH1A1 2742/4885 |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | MEN1 1390/4885KMT2A 1984/4885ALDH1A1 1971/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | MEN1 1550/4885KMT2A 2363/4885ALDH1A1 3735/4885 |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | STUB1, MDM2, USP30 | MEN1 1550/4885KMT2A 2363/4885ALDH1A1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.